Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
| Autor: | Mahaffey, KW, Neal, B, Perkovic, V, De Zeeuw, D, Fulcher, G, Erondu, N, Shaw, W, Fabbrini, E, Sun, T, Li, Q, Desai, M, Matthews, DR, CANVAS Program Collaborative Group |
|---|---|
| Přispěvatelé: | Groningen Kidney Center (GKC) |
| Rok vydání: | 2017 |
| Předmět: |
Male
Time Factors medicine.medical_treatment Placebo-controlled study RATIONALE 030204 cardiovascular system & hematology PLACEBO-CONTROLLED TRIAL DISEASE 0302 clinical medicine DESIGN Risk Factors Original Research Articles Clinical endpoint Secondary Prevention Myocardial infarction Canagliflozin OUTCOMES CANVAS Program Collaborative Group clinical trial Middle Aged Hospitalization Primary Prevention Treatment Outcome 1117 Public Health And Health Services Cardiovascular Diseases SAFETY Cohort diabetes mellitus ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female Cardiology and Cardiovascular Medicine medicine.drug Adult medicine.medical_specialty 030209 endocrinology & metabolism 1102 Cardiovascular Medicine And Haematology 03 medical and health sciences Double-Blind Method Physiology (medical) Internal medicine Diabetes mellitus BASE-LINE CHARACTERISTICS medicine Hypoglycemic Agents Humans Renal replacement therapy Sodium-Glucose Transporter 2 Inhibitors Aged business.industry Type 2 Diabetes Mellitus 1103 Clinical Sciences medicine.disease Surgery Cardiovascular System & Hematology Diabetes Mellitus Type 2 business |
| Zdroj: | Circulation Circulation, 137(4), 323-334. LIPPINCOTT WILLIAMS & WILKINS |
| ISSN: | 1524-4539 0009-7322 |
| Popis: | Supplemental Digital Content is available in the text. Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk. The comparative effects among participants with and without a history of cardiovascular disease (secondary versus primary prevention) were prespecified for evaluation. Methods: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) randomly assigned 10 142 participants with type 2 diabetes mellitus to canagliflozin or placebo. The primary prevention cohort comprised individuals ≥50 years of age with ≥2 risk factors for cardiovascular events but with no prior cardiovascular event, and the secondary prevention cohort comprised individuals ≥30 years of age with a prior cardiovascular event. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included heart failure hospitalization and a renal composite (40% reduction in estimated glomerular filtration rate, renal replacement therapy, or renal death). Results: Primary prevention participants (N=3486; 34%) were younger (63 versus 64 years of age), were more often female (45% versus 31%), and had a longer duration of diabetes mellitus (14 versus 13 years) compared with secondary prevention participants (N=6656; 66%). The primary end point event rate was higher in the secondary prevention group compared with the primary prevention group (36.9 versus 15.7/1000 patient-years, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|